NASDAQ:VANI Vivani Medical Q4 2024 Earnings Results & Report $0.98 -0.15 (-12.97%) Closing price 11/12/2026 04:00 PM EasternExtended Trading$0.98 -0.01 (-0.85%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Vivani Medical missed analyst earnings expectations in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$0.11 versus the -$0.10 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 31, 2025TimeBefore Market OpensConference Call8:30 AM ET Vivani Medical EPS ResultsActual EPS-$0.11Consensus EPS -$0.10Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersVivani Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Vivani Medical Q4 2024 Earnings FAQ Did Vivani Medical beat earnings estimates for Q4 2024? Vivani Medical (NASDAQ:VANI) reported earnings of -$0.11 per share for Q4 2024, missing the consensus estimate of -$0.10. The report was announced on Monday, March 31, 2025. Vivani Medical Earnings HeadlinesVivani Medical Reports Positive Phase 1 Results For Semaglutide Implant NPM-139; Stock DownNovember 12 at 1:20 PM | rttnews.comVivani's Q3 Loss Widens Mildly To $7 Mln; Data For GLP-1 Implant Expected Later This WeekNovember 12 at 8:17 AM | rttnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 13 at 1:00 AM | Weiss Ratings (Ad)Vivani Nears Key Data Readout For Obesity ImplantNovember 12 at 8:17 AM | rttnews.comVivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in ...November 12 at 8:17 AM | marketscreener.comMVivani Medical Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 11 at 4:05 PM | globenewswire.comSee More Vivani Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email. Email Address About Vivani MedicalVivani Medical (NASDAQ:VANI) is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence. The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes. Vivani has also pursued additional implantable programs involving therapies such as semaglutide for obesity and related metabolic conditions. Vivani Medical is based in the United States and is led by President and Chief Executive Officer Adam Mendelsohn, Ph.D. As an emerging biotechnology company, Vivani’s product candidates remain subject to clinical development and regulatory review, and the company’s programs may change as research progresses.View Vivani Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
